Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 18/20 | 0.66 |
| ▸ | PTK2B | Q14289 | 13/20 | 0.66 |
| ▸ | AURKA | O14965 | 2/20 | 0.66 |
| ▸ | PLK4 | O00444 | 1/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.66 |
| ▸ | STK16 | O75716 | 1/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.66 |
| ▸ | PAK4 | O96013 | 1/20 | 0.66 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.66 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.66 |
| ▸ | PRKCG | P05129 | 1/20 | 0.66 |
| ▸ | INSR | P06213 | 1/20 | 0.66 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
| ▸ | CDK1 | P06493 | 1/20 | 0.66 |
| ▸ | LYN | P07948 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498820 | 0.94 | PTK2B (0.75) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5185861 | 0.90 | PTK2 (0.69) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5185849 | 0.88 | PTK2 (0.67) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5184792 | 0.87 | PTK2B (0.67) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5185184 | 0.87 | PTK2 (0.72) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5186538 | 0.87 | PTK2 (0.70) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5187429 | 0.87 | PTK2 (0.69) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5185856 | 0.87 | PTK2 (0.72) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5185891 | 0.87 | PTK2 (0.72) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5199163 | 0.86 | PTK2B (0.59) | PTK2PTK2BAURKAPLK4PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751142-A1 | PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-02-14 | — | — | EP | claimed |
| US-7145008-B2 | Selective inhibitors of certain receptor and non-receptor tyrosine kinases such as FAK (focal adhesion kinase); anticancer agents; N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-4-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide for example | PFIZER INC (US) | 2006-12-05 | — | — | US | claimed |
| WO-2005111022-A1 | PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050256125-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC. | 2005-11-17 | — | — | US | claimed |
| EP-1751142-A1 | PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7145008-B2 | Selective inhibitors of certain receptor and non-receptor tyrosine kinases such as FAK (focal adhesion kinase); anticancer agents; N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-4-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide for example | PFIZER INC (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2005111022-A1 | PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256125-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256125-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | DPYD, TYMP, TYMS | PTK2 4505/4885PTK2B 4237/4885AURKA 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.